Biocon Biologics: Biocon Biologics inks licence pact with Janssen for biosimilar product

The agreement licenses the company to launch in the US in February 2025, once approved by the US Food and Drug Administration(USFDA), Biocon Biologics said in a statement.

Related Keywords

United States ,Stelara Ustekinumab ,Biocon Biologics ,Trademarks Office ,Drug Administration ,Biocon Ltd ,Inter Partes Review ,Patent Trial ,Appeal Board ,